# Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART

Study · id `cardio:ct-nct02311231` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02311231](<https://clinicaltrials.gov/study/NCT02311231>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02311231

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6012 participants.

## Technical summary

Registry record NCT02311231. Randomized; no masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2017-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 6012 participants (enrolled count; ClinicalTrials.gov record NCT02311231, source copy `cardio:ctgov-nct02311231-2017-05-19`, retrieved 2026-10-26)
- Start date: 2014-06 (registry gives no type) (ClinicalTrials.gov record NCT02311231, source copy `cardio:ctgov-nct02311231-2017-05-19`, retrieved 2026-10-26)
- Primary completion: 2017-03 (actual) (ClinicalTrials.gov record NCT02311231, source copy `cardio:ctgov-nct02311231-2017-05-19`, retrieved 2026-10-26)
- Completion: 2017-03 (actual) (ClinicalTrials.gov record NCT02311231, source copy `cardio:ctgov-nct02311231-2017-05-19`, retrieved 2026-10-26)
- Countries: Sweden (ClinicalTrials.gov record NCT02311231, source copy `cardio:ctgov-nct02311231-2017-05-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02311231-2017-05-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART
- Acronym: VALIDATE
- Condition: ST-segment Elevation Myocardial Infarction
- Condition: Non ST-segment Elevation Myocardial Infarction
- Intervention (Drug): bivalirudin
- Intervention (Drug): Heparin
- Lead sponsor: Uppsala University
- Lead sponsor class: OTHER
- Collaborator: Lund University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record: Bivalirudin (`cardio:bivalirudin`)
- Registry intervention name matches this record: Heparin (`cardio:heparin`)
- Registry intervention is a member of this class by a sourced record link: Anticoagulants (`cardio:anticoagulants`)
- Registry lists this organization as the lead sponsor: Uppsala University (`cardio:org-uppsala-university`)
- Registry lists this organization as a collaborator: Lund University (`cardio:org-lund-university`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Bivalirudin versus Heparin Monotherapy in Myocardial Infarction (`cardio:pubmed-28844201`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Bivalirudin Versus Heparin Monotherapy in ST-Segment-Elevation Myocardial Infarction (`cardio:pubmed-34903034`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Bivalirudin versus heparin in ST and non-ST-segment elevation myocardial infarction-Outcomes at two years (`cardio:pubmed-38575449`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 776326987c1229c4cea346a75cdabe8eca0dc76c002450e4e80d4ebadfc8beeb
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
